×

Durata Therapeutics to Present Five Posters at IDWeek 2014

CHICAGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that it will present five posters highlighting data from its recently launched product, DALVANCE™ (dalbavancin) for injection, at IDWeek 2014, which takes place from October 8-11, 2014 in Philadelphia, PA.

Thursday, October 9, 2014

Title: Dalbavancin Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subanalysis from the DISCOVER Studies

Authors: Sailaja Puttagunta, MD, Helen Boucher, MD, FIDSA, George Talbot, MD, Mark Wilcox, MD and Michael Dunne, MD, Durata Therapeutics, Branford, CT, Tufts New England Medical Center, Boston, MA, Talbot Advisors LLC, Anna Maria, FL, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom

Poster #: 266

Title: Dalbavancin for the Treatment of Streptococcal Skin Infections

Authors: Sailaja Puttagunta, MD and Michael Dunne, MD, Durata Therapeutics, Branford, CT

Poster #: 267

Title: Pharmacokinetics of Dalbavancin (DAL) in Bone and Associated Tissues in Patients Undergoing Orthopedic Surgical Procedures

Authors: James Baldassarre, MD, Scott Van Wart, M.S., Alan Forrest, PharmD, Christopher Rubino, Pharm D and Michael Dunne, MD, Durata Therapeutics, Branford, CT, Institute for Clinical Pharmacodynamics, Latham, NY, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

Poster #: 398

Friday, October 10, 2014

Title: Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by Vancomycin Dosing Regimen and Vancomycin Trough Serum Concentrations in the DISCOVER Program

Authors: Sailaja Puttagunta, MD, Mark Wilcox, MD, Helen Boucher, MD, FIDSA, George Talbot, and Michael Dunne, MD, Durata Therapeutics, Branford, CT, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Tufts New England Medical Center, Boston, MA, Talbot Advisors LLC, Anna Maria, FL

Poster #: 675

Saturday, October 11, 2014

Title: ASO and DNase Titers in Patients with Streptococcal Skin Infections in the Dalbavancin DISCOVER Program

Authors: Sailaja Puttagunta, MD and Michael Dunne, MD, Durata Therapeutics, Branford, CT

Poster #: 1345

The abstracts are currently available on the IDWeek website at www.idweek.org and copies of the posters will be available on October 8, 2013 at 12:01am EDT at www.duratatherapeutics.com.

About DALVANCE (dalbavancin) for injection

DALVANCE is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. DALVANCE is the first and only IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. DALVANCE demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Streptococcus pyogenes, as well as certain other streptococcal species.

For important prescribing and safety information, see www.dalvance.com.

DALVANCE is a trademark of Durata Therapeutics Holding C.V.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

Forward-looking Statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

CONTACT: Allison Wey Durata Therapeutics, Inc. Vice President, Investor Relations and Public Affairs (312) 219-7017 awey@duratatherapeutics.com

Source:Durata Therapeutics, Inc.